6430537H07Rik Activators
6430537H07Rik Activators encompass a range of chemical compounds that indirectly augment the functional activity of 6430537H07Rik by manipulating various signaling pathways within the cell. Forskolin, by increasing intracellular cAMP, indirectly supports the functional role of 6430537H07Rik through PKA activation, which phosphorylates downstream targets to enhance 6430537H07Rik activity. Similarly, IBMX and Rolipram, by inhibiting phosphodiesterases, elevate cAMP, reinforcing PKA signaling and 6430537H07Rik enhancement. Zaprinast boosts cGMP levels, potentially engaging cGMP-dependent protein kinases that may serve to enhance 6430537H07Rik. Modulators of calcium signaling such as A23187 and BAPTA-AM influence calcium-dependent pathways, which may indirectly enhance 6430537H07Rik activity. PMA acts as a PKC activator, initiating phosphorylation cascades that could enhance 6430537H07Rik, while Y-27632 and Blebbistatin, by inhibiting ROCK kinase and myosin II ATPase respectively, adjust the cytoskeletal dynamics, possibly leading to an enhancement of 6430537H07Rik-related signaling.
The influence on 6430537H07Rik is further modulated by compounds that target specific kinases and phosphatases. ML-7, by inhibiting MLCK, and PD98059, as a MEK inhibitor, may indirectly favor pathways that enhance 6430537H07Rik. LY294002, a PI3K inhibitor, could shift the balance of intracellular signaling towards pathways thatThe influence on 6430537H07Rik is further modulated by compounds that target specific kinases and phosphatases. ML-7, by inhibiting MLCK, and PD98059, as a MEK inhibitor, may indirectly favor pathways that enhance 6430537H07Rik. LY294002, a PI3K inhibitor, could shift the balance of intracellular signaling towards pathways that indirectly enhance the functionality of 6430537H07Rik by altering Akt pathway signaling. These activators, through their multifaceted actions on different cellular signaling mechanisms, collectively contribute to the upregulation of 6430537H07Rik activity without necessitating direct binding or action on 6430537H07Rik itself, illustrating the complex interplay of cellular signaling in protein regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, increasing cAMP levels and enhancing 6430537H07Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C, which can phosphorylate substrates to enhance 6430537H07Rik function. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a calcium ionophore, increasing intracellular Ca2+ and activating Ca2+-dependent proteins that could enhance 6430537H07Rik. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective PDE4 inhibitor, increasing cAMP levels thereby potentially enhancing 6430537H07Rik via PKA-dependent signaling. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast, a PDE5 inhibitor, raises cGMP levels, which may enhance 6430537H07Rik through cGMP-dependent protein kinases. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits ROCK kinase, altering cytoskeletal dynamics and potentially enhancing 6430537H07Rik through stress fiber formation changes. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Blebbistatin inhibits myosin II ATPase, affecting cytoskeletal tension and possibly enhancing 6430537H07Rik related signaling. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 inhibits MLCK, leading to decreased myosin light chain phosphorylation and affecting cellular mechanics that might enhance 6430537H07Rik. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM is a calcium chelator that can modulate calcium signaling, potentially enhancing 6430537H07Rik indirectly via calcium-dependent pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that may shift signaling towards pathways that enhance 6430537H07Rik without direct activation of the protein. | ||||||